(redirected from ACVR1)
Also found in: Dictionary, Medical, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for fop

a man who is much concerned with his dress and appearance

Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
Now, open science company M4K Pharma has taken on development of the ACVR1 inhibitor drugs - with clinical trials on sufferers expected to begin in 2021.
TP-0184 is small molecule inhibitor of ACVR1, which is involved in the transforming growth factor beta signaling pathway.
This condition is linked to a heterozygous mutation of the Activin A Receptor type 1 (ACVR1) gene expressing a protein that encodes histidine (H) ratber than arginine (R) at residue 206 (R206H).
The ACVR1 gene, also downregulated in differentiated MyoD KO QM7#4 cells, plays an important role in the bone morphogenic protein pathway, which is responsible for the development and repair of the skeletal system [28].
(b) qRT-PCR analysis of expression levels of lncRNA (PART1) and mRNAs (ACVR1, E2F3, and VEGFA) in ceRNA network.
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.
Classical clinical findings are diagnostic and should be made before the appearance of heterotopic bone through genetic analysis of ACVR1 mutation.
Ahmed et al., "The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations," Journal of Medical Genetics, vol.
Up-regulation of the expression of TGF-[beta] and TGF-[beta] receptors type I and II (ACVR1 and TGFBR2) by NF3 suggests the initiation of the TGF-[beta] signaling pathway.
It is an autosomal dominant trait and affected persons have mutations in the activin A type 1 receptor gene (ACVR1), chromosomal locus 2q23-24.
In contrast, mRNA levels of interferon gamma receptor 1 (IFNGR1), activin A receptor, type 1 (ACVR1), and activated leukocyte cell adhesion molecule (ALCAM) all exhibited downregulation in study subjects of the high-level arsenic exposure group.
FOP is caused by a mutation in the gene for ALK2, which is known as ACVR1, that causes hypersensitivity to certain bone morphogenetic proteins and a neomorphic response to activins.
It is caused by mutations in the ACVR1 gene, which encodes Activin-A receptor type 1, an important protein in the bone morphogenetic protein (BMP) pathway.
Professors Toguchida and Ikeya have been working together to study how the ACVR1 mutation causes FOP and had been focusing on the signalling of Bone Morphogenetic Protein (BMP) until Kyosuke Hino, a visiting scientist from the Sumitomo Dainippon Pharma Corporation, showed that the ACVR1 mutation also activates the signalling of Activin-A.